JERUSALEM, March 21 (Reuters) - Israel’s Teva Pharmaceutical Industries (TEVA.O: Quote, Profile, Research), the world’s largest generic drugmaker, has halted the development of an oral version of its popular multiple sclerosis drug Copaxone, the company said.
